Molina Earnings call 10/23/25

Molina Healthcare's Third Quarter 2025 Earnings Call Notes

Call Introductory Remarks

  • Date and Format of Call:

    • Third quarter earnings call for Molina Healthcare held on Thursday, October 23, 2025.

    • All participants in listen-only mode, with questions accessible through telephone keypad (star then 1 to ask, star then 2 to withdraw).

  • Participants Present:

    • Jeffrey Guyer - Vice President, Investor Relations.

    • Joe Zaretsky - President and CEO.

    • Mark Kine - Chief Financial Officer (CFO).

  • Recording Notice:

    • The event is recorded, and playback will be available for 30 days.

  • Earnings Release:

    • A press release was issued after market close on the day prior, available on the Investor Relations website.

  • Forward-Looking Statements:

    • Statements about 2025 guidance, 2026 outlook, medical cost trends, Medicaid rate adjustments, marketplace pricing, and activity in mergers and acquisitions (M&A) are forward-looking and subject to risks.

    • Caution is advised as actual results may differ from expectations; reference risk factors in Form 10-K, Form 10-Q, or Form 8-K filings with the SEC.

Financial Performance Overview

  • Third Quarter Highlights:

    • Adjusted earnings per share (EPS): $1.84.

    • Premium revenue reported: $10.8 billion.

    • Consolidated Medical Care Ratio (MCR): 92.6% reflecting a challenging medical cost environment.

    • Adjusted pretax margin: 1%.

    • Underperformance primarily from the marketplace business, whereas Medicaid showed strong margins despite pressure.

  • Year-to-Date Performance:

    • Consolidated MCR: 90.8%.

    • Adjusted pretax margin for the year: 2.7%.

  • Segment Performance:

    • Medicaid:

    • MCR: 92% (75% of total premium revenue).

    • Adjusted pretax margin constrained.

    • Medicare:

    • MCR: 93.6% indicating high acuity population affects.

    • Focus on LTSS and high-cost drugs.

    • Marketplace:

    • MCR: 95.6%, utilized significantly above expectations.

2025 Guidance Update

  • Revised Full-Year Premium Revenue Guidance:

    • Increase to approximately $42.5 billion.

    • Adjusted EPS guidance expected at $14 per share, significantly down from prior guidance of $19 per share.

    • MCR projected at 91.3% and pretax margin at 2.1%.

  • Contribution to EPS Reduction:

    • Half attributed to marketplace business (10% of overall business).

    • Medicaid and Medicare contributing lesser amounts to reductions.

  • Segment-Specific Guidance:

    • Medicaid:

    • Projected NCR for the year at 91.5%; expected pretax margin of 3.2%.

    • Average rate increase expectancy: 5.5% with medical cost trend at 7%.

    • Medicare:

    • Full-year MCR of 91.3%; breakeven margin.

    • Marketplace:

    • Full-year MCR forecasted at 89.7%, negative pretax margin.

2026 Outlook

  • Early Thoughts for 2026:

    • Anticipated new contracts impacting premium revenue growth and achieving target of $46 billion.

    • Pricing strategy anticipated to lessen marketplace exposure but anticipated to impact revenue

    • Baseline EPS thoughts consider Medicaid performance translating into $6.50 per share.

  • Key Factors for EPS in 2026:

    • Normal rate seasonality pressures and anticipated billed rates beneficial.

    • Potential earnings upside from improved Medicaid risk rates, dual eligibles growth, marketplace management.

Growth Initiatives and M&A Activity

  • Continued growth endeavors despite margin challenges.

  • Successful RFP renewals, including Wisconsin My Choice contract.

  • Active pipeline for Medicaid contracts and M&A opportunities expected to bolster capacity and revenue.

  • Deployment of capital intended for accretive acquisitions, especially in Medicaid space.

Financial Summary by Mark Kine

  • Third Quarter Financials:

    • Total revenue: ~$11 billion with $10.8 billion premium revenue and adjusted EPS of $1.84.

    • Consolidated MCR maintained at 92.6%, indicating ongoing medical trend challenges.

  • Key Variances:

    • Marketplace underperformed, leading to significant impact across segments.

    • Continued medical cost pressure from categories like behavioral health and pharmacy.

  • Balance Sheet Insights:

    • Strong capital position, positive cash flow driven by parent dividends, notable share repurchases ($500 million worth of 2.8 million shares). Debt ratio approximated 48%.

  • 2025 Guidance Reiterations:

    • Premium revenue guidance steady at $42.5 billion.

    • EPS noted at $14 reflects higher MCR forecast.

  • Building Blocks for 2026 Expected Revenue and EPS:

    • Involves growth strategies, Medicaid contracts, and potential M&A activity outcomes.

    • Management anticipates revenue challenges but optimistic on reform prospects and future profitability.